-
1 Comment
CCM Duopharma Biotech Berhad is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 45.5% cheaper than other stocks from the Other sector with a price to sales ratio of 3.5.
CCM Duopharma Biotech Berhad's total revenue sank by 6.4% to $134M since the same quarter in the previous year.
Its net income has dropped by 4.9% to $14M since the same quarter in the previous year.
Finally, its free cash flow grew by 503.0% to $6M since the same quarter in the previous year.
Based on the above factors, CCM Duopharma Biotech Berhad gets an overall score of 2/5.
| CurrencyCode | MYR |
|---|---|
| Exchange | KLSE |
| ISIN | MYL7148OO009 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 1B |
|---|---|
| PE Ratio | 12.1 |
| Target Price | 1.69 |
| Dividend Yield | 3.8% |
| Beta | 0.36 |
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain products under the Donna brand name; skincare products under Dermoplex brand name; cosmeceuticals under the IRORO Nutreatment brand name; and functional food under the CHAMPS Nutribar and PROVITON STR Powerz brand names. The company also provides generic drugs for various therapeutic areas, such as cardiovascular, dermatology, hormonal, respiratory, sensory and nervous system, musculoskeletal, anti-infectives, and others; and specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables for the treatment of diabetes, cancer, cardiovascular, renal, and other diseases. In addition, it engages in the development of small molecules and biologic therapies for the treatment of Alzheimer's disease; digital therapeutics; and stem cell therapies. Further, the company is involved in property management and services; and distribution of chemical products. It exports its products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 7148.KLSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
